The effect of a multispecies probiotic on microbiota composition in a clinical trial of patients with diarrhea‐predominant irritable bowel syndrome

Hod, Keren; Dekel, Roy; Cohen, Nathaniel A.; Sperber, Ami D.; Ron, Yishai; Boaz, Mona; Berliner, Shlomo; Maharshak, Nitsan

doi:10.1111/nmo.13456

Cited by 46 publications

(40 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Non‐responders exhibited a greater number of more abundant bacteria than responders including Streptococcus , Dorea , and Rumicococcus gnavus (a species suggested to be a potential biomarker of IBS). The results of this study are in line with the data presented by Hod et al, indicating that fecal bacterial patterns at baseline may be predictive of response to intervention influencing gut microbiota. All together these data suggest that patient responsiveness to interventions targeting dysbiosis may be linked to intestinal microbial ecosystem, suggesting a need for tailored therapies.…”

Section: Clinical and Biological Predictors Of Responsiveness To Probsupporting

confidence: 92%

“…Indeed, a functional rather than structural effect of probiotics is in line with evidence from a systematic review of seven studies showing that probiotics did not modify the main components of endogenous microbiota . These results are also in keeping with the data reported by Hod et al in this issue of Neurogastroenterology and Motility, indicating that the impact of probiotics in the modulation of intestinal microbial ecosystem is limited. The putative functional mechanisms underlying probiotic improvement of gut dysbiosis, and the metabolic pathways leading to IBS symptom improvement is at this time only speculative and requires further investigation in ad hoc studies.…”

Section: Dysbiosis As Possible Target Of Probiotic Treatment In Ibssupporting

confidence: 88%

“…In addition, it is questionable that the same probiotic strategy can be equally effective in all patients with IBS, as demonstrated by a recent study reporting dissimilar results in patients with IBS‐C (symptoms worsened) as compared to patients with IBS‐D or IBS‐M (improved) . Female gender may be more likely to respond to probiotic treatment, as suggested by trials performed only in women with IBS as the study of Hod et al, but this will require further studies.…”

Section: Clinical and Biological Predictors Of Responsiveness To Probmentioning

confidence: 99%

“…IBS is still largely characterized by the lack of reliable biological markers . In this context, the identification of microbial signatures that may act as biomarkers and predict clinical response to specific probiotic interventions is welcome …”

Section: Future Perspectives and Conclusionmentioning

confidence: 99%

“…In this issue of Neurogastroenterology and Motility, Hod et al assessed the impact of a multispecies probiotic (BIO‐25) on gut microbiota composition in women with irritable bowel syndrome with diarrhea (IBS‐D) as well as biological and clinical predictors of therapeutic response. The authors analyzed biological samples obtained in a previously published double‐blind, placebo‐controlled study performed on 107 women with IBS‐D.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Probiotics in irritable bowel syndrome: Where are we?

Barbara

Cremon

Azpiroz

2018

Neurogastroenterology Motil

View full text Add to dashboard Cite

We have only recently begun to understand how alterations of the intestinal microbial ecosystem lead to the disruption of host‐microbial interactions and are associated with diseases, including functional gastrointestinal disorders such as irritable bowel syndrome (IBS). Although we are still far from understanding the human microbiome, gut microbiota is already a therapeutic target. Probiotics are live microorganisms that, when administered in adequate amounts, confer a health benefit to the host and may represent a therapeutic option for diseases characterized by dysbiosis such as IBS. Meta‐analyses suggest that probiotics provide a therapeutic gain over placebo on global symptoms with a high safety profile in IBS patients. However, the mechanisms by which they provide benefit in IBS remain virtually unknown. In this issue of Neurogastroenterology and Motility, BIO‐25, a multispecies probiotic, did not significantly modify the composition of the fecal microbiota, but interestingly, patients with specific basal features of the intestinal microbial ecosystem improved with treatment. Based on these data, it is tantalizing to speculate that microbiota composition serves as a predictor of the response to probiotic intervention. This mini‐review addresses unresolved issues related to mechanisms through which probiotics may exert their beneficial effects, the biological, as well as clinical predictors of favorable outcomes in IBS and finally considers possible new directions for future studies.

show abstract

Section: Clinical and Biological Predictors Of Responsiveness To Probsupporting

confidence: 92%

Section: Dysbiosis As Possible Target Of Probiotic Treatment In Ibssupporting

confidence: 88%

Section: Clinical and Biological Predictors Of Responsiveness To Probmentioning

confidence: 99%

Section: Future Perspectives and Conclusionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Probiotics in irritable bowel syndrome: Where are we?

Barbara

Cremon

Azpiroz

2018

Neurogastroenterology Motil

View full text Add to dashboard Cite

show abstract

Yogurt Supplementation Can Ameliorate Fatty Liver Diseases and Metabolic Syndrome in High Fat‐Induced Conditions in Mice

Hasan,

Amin,

Mia

et al. 2024

Food Science & Nutrition

View full text Add to dashboard Cite

Hepatic steatosis/non‐alcoholic fatty liver disease is a major public health delinquent caused by the excess deposition of lipid into lipid droplets (LDs) as well as metabolic dysregulation. Hepatic cells buildup with more fat molecules when a person takes high fat diet that is excessive than the body can handle. At present, millions of people in the world are affected by this problem. So, it is very important to know the effects of factors responsible for the disease. Here, the role of lipid droplet (LD) biogenesis and metabolism was analyzed and intended to investigate if defects in biogenesis/metabolic enzymes are responsible for the accumulation of lipids other than LDs in fatty liver disease in high‐fat‐induced conditions in mice model. To explore it, high‐fat diet (HFD), fast food (FF), and soft drinks (SD) were administered to wild‐type Swiss albino mice for 14 weeks following yogurt supplementation. After experimental period, glucose tolerance, enzyme function, lipid profile, plasma biochemistry, and other analytical tests were analyzed by auto‐analyzer including different oxidative stress markers. Lipids from hepatic tissues were extracted, and purified by Floatation Assay and subsequently analyzed by different biochemical and chromatographic techniques. Histological architecture of hepatocytes was performed using Zeiss microscope. Finally, increased amount of lipids biogenesis/accumulation was found in liver tissues that causes Fatty liver disease. Significantly, HFD, FF, and SD were identified as factors for the increased LD biogenesis and or lipid metabolic disorder. Nevertheless, yogurt supplementation can homeostasis those LD formation and metabolic syndrome as it increases the down regulation of lipid biogenesis as well as lipid metabolic rate. So, yogurt supplementation was considered as a novel agent for decreasing LD biogenesis as well as excessive accumulation of fat in hepatocytes which can be used as therapeutics for the treatment of NAFLD.

show abstract

Effects of dietary supplementation with multispecies probiotics on intestinal epithelial development and growth performance of neonatal calves challenged with Escherichia coli K99

Nie

et al. 2022

J Sci Food Agric

View full text Add to dashboard Cite

BACKGROUND Probiotics exhibit antibiotic properties and are capable of treating certain bacterial infections, including diarrhea. Therefore, the aim of this study is to investigate the effects of dietary supplementation with multispecies probiotic (MSP) on diarrhea, average daily gain (ADG) and intestinal development of neonatal calves challenged with Escherichia coli K99. RESULTS Thirty‐six neonatal Holstein calves were randomly assigned to three treatment groups. After E. coli K99 challenge, calves in the control (C) and MSP treatment groups had significantly higher ADG and feed efficiency, and significantly lower fecal scores than those of calves in the diarrhea (D) group. The mean time of diarrhea resolution was 4.5 and 3.1 days for calves in the D and MSP treatment groups, respectively. Furthermore, the structures of the various segments (duodenum, jejunum and ileum) of the small intestine of the calves, activities of several small intestinal enzymes, and expression of several energy metabolism‐related genes in the small intestine segments were significantly affected by MSP treatments. CONCLUSION Dietary supplementation of MSP had a positive effect in treating calf diarrhea; it improved ADG and feed efficiency and promoted development of the small intestine. © 2022 The Authors. Journal of The Science of Food and Agriculture published by John Wiley & Sons Ltd on behalf of Society of Chemical Industry.

show abstract

The effect of a multispecies probiotic on microbiota composition in a clinical trial of patients with diarrhea‐predominant irritable bowel syndrome

Abstract: Identifying patients with a more amenable microbiome at treatment initiation may result in better treatment response.

Cited by 46 publications

References 34 publications

Probiotics in irritable bowel syndrome: Where are we?

Probiotics in irritable bowel syndrome: Where are we?

Yogurt Supplementation Can Ameliorate Fatty Liver Diseases and Metabolic Syndrome in High Fat‐Induced Conditions in Mice

Effects of dietary supplementation with multispecies probiotics on intestinal epithelial development and growth performance of neonatal calves challenged with Escherichia coli K99

Contact Info

Product

Resources

About